» Articles » PMID: 1420159

Mammalian Facilitative Glucose Transporters: Evidence for Similar Substrate Recognition Sites in Functionally Monomeric Proteins

Overview
Journal Biochemistry
Specialty Biochemistry
Date 1992 Oct 27
PMID 1420159
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Four facilitative glucose transporters isoforms, GLUT1/erythrocyte, GLUT2/liver, GLUT3/brain, and GLUT4/muscle-fat, as well as chimeric transporter proteins were expressed in Xenopus oocytes, and their properties were studied. The relative Km's of the transporters for 2-deoxyglucose were GLUT3 (Km = 1.8 mM) > GLUT4 (Km = 4.6 mM) > GLUT1 (Km = 6.9 mM) > GLUT2 (Km = 17.1 mM). In a similar fashion, the uptake of 2-deoxyglucose by GLUT1-, GLUT2-, and GLUT3-expressing oocytes was inhibited by a series of unlabeled hexoses and pentoses and by cytochalasin B in a similar hierarchical order. To determine if the functional unit of the glucose transporter was a monomer or higher-order multimer, the high-affinity transporter GLUT3 was coexpressed with either the low-affinity GLUT2 or a GLUT3 mutant which contained a transport inactivating Trp410-->Leu substitution. In oocytes expressing both GLUT2 and GLUT3, the transport activity associated with each transporter isoform could be distinguished kinetically. Similarly, there was no alteration in the kinetic parameters of GLUT3, or the ability of glucose or cytochalasin B to inhibit 2-deoxyglucose uptake, when coexpressed with up to a 3-fold greater amount of functionally inactive mutant of GLUT3. These studies suggest that the family of glucose transporters have similar binding sites which may be in the form of a functional monomeric unit when expressed in Xenopus oocytes.

Citing Articles

Metabolic adaptations to acute glucose uptake inhibition converge upon mitochondrial respiration for leukemia cell survival.

Komza M, Khatun J, Gelles J, Trotta A, Abraham-Enachescu I, Henao J Cell Commun Signal. 2025; 23(1):47.

PMID: 39863913 PMC: 11762851. DOI: 10.1186/s12964-025-02044-y.


Targeting the Leloir Pathway with Galactose-Based Antimetabolites in Glioblastoma.

Sharpe M, Ijare O, Raghavan S, Baskin A, Baskin B, Baskin D Cancers (Basel). 2024; 16(20).

PMID: 39456605 PMC: 11506710. DOI: 10.3390/cancers16203510.


Glucose metabolism impairment as a hallmark of progressive myoclonus epilepsies: a focus on neuronal ceroid lipofuscinoses.

Santucci L, Bernardi S, Vivarelli R, Santorelli F, Marchese M Front Cell Neurosci. 2024; 18:1445003.

PMID: 39364042 PMC: 11447523. DOI: 10.3389/fncel.2024.1445003.


Mitochondrial metabolism: A moving target in hepatocellular carcinoma therapy.

Komza M, Chipuk J J Cell Physiol. 2024; 240(1):e31441.

PMID: 39324415 PMC: 11732733. DOI: 10.1002/jcp.31441.


Genetically engineering glycolysis in T cells increases their antitumor function.

Toledano Zur R, Atar O, Barliya T, Hoogi S, Abramovich I, Gottlieb E J Immunother Cancer. 2024; 12(7).

PMID: 38964783 PMC: 11227835. DOI: 10.1136/jitc-2023-008434.